This article is more than 5 years old. Information may no longer be current.
Predictive model for type 2 diabetes could improve heart outcomes
Click Here to Manage Email Alerts
Geisinger and Boehringer Ingelheim in collaboration with Eli Lilly and Company are developing a risk-prediction model to improve health outcomes, including cardiovascular death, kidney failure and hospitalization for heart failure, in people with type 2 diabetes, according to a press release.
Despite recent advancements, CVD remains the leading cause of death for people with diabetes.
The predictive model, to be created using Geisinger’s de-identified electronic health records, will aim to provide more precise treatment pathways.
“Our partnership with Boehringer Ingelheim will use real-world data and predictive modeling to deploy precision health care strategies to bring the most value to the people we care for,” said Brent A. Williams, PhD, assistant professor of epidemiology at Geisinger. “We hope the knowledge gained from this predictive model can help health care providers better target their treatment recommendations for people with type 2 diabetes and, as a result, lower their risk for these serious diabetes-related consequences.”
Disclosure: Williams is an employee of Geisinger.